Pharma firm Roche's drug cocktail doubles chance of holding lung cancer at bay - News Summed Up

Pharma firm Roche's drug cocktail doubles chance of holding lung cancer at bay


Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented. Roche's November announcement that its Impower 150 trial had broadly succeeded in first-line lung cancer patients helped spur a one-day, $12 billion rally in the Basel-based drugmaker's market capitalization. Roche Chief Executive Severin Schwan sees an opportunity to leap-frog ahead as competitors still await their own lung cancer combination trial results. Patients getting Roche's immunotherapy survived an average of 8.3 months without their disease getting worse, compared with a PFS of 6.8 months for those getting chemotherapy and Avastin. Tecentriq is already approved in bladder cancer treatment and for lung cancer patients who have failed chemotherapy.


Source: dna December 07, 2017 06:56 UTC


Loading...
Loading...